Evidence map›Paper›PMID 41807585›Full record

ArticleCommunications biology2026

Deep learning-based in silico labeling for analyzing morphological features of MSCs to predict immunomodulatory capacity.

Zhiyu Liu, Gang An, Xiao Liang, Xumin Wu, Junyuan Hu, Haijun Wang, Jingfeng Ou, Xiuping Zeng, Zhiliang Xia, Kaixiang Hou and 5 more

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhiyu Liu *Shenzhen Cellauto Automation Co., Ltd, Shenzhen, China.
Gang An *Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.
Xiao Liang *Harbin Beike Health Technology Co., Ltd, Harbin, China.
Xumin Wu *Shenzhen Cellauto Automation Co., Ltd, Shenzhen, China.
Junyuan HuHarbin Beike Health Technology Co., Ltd, Harbin, China.
Haijun WangShenzhen Cellauto Automation Co., Ltd, Shenzhen, China.
Jingfeng OuFaculty of Computer Science and Control Engineering, Shenzhen University of Advanced Technology, Shenzhen, China.
Xiuping ZengHarbin Beike Health Technology Co., Ltd, Harbin, China.
Zhiliang XiaFaculty of Computer Science and Control Engineering, Shenzhen University of Advanced Technology, Shenzhen, China.
Kaixiang HouShenzhen Kenuo Medical Laboratory, Shenzhen, China.
Wanglong ChuHarbin Beike Health Technology Co., Ltd, Harbin, China.
Jianbin YeShenzhen Cellauto Automation Co., Ltd, Shenzhen, China.
Cui LiaoShenzhen Cellauto Automation Co., Ltd, Shenzhen, China.
Zhengmian ZhangFujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China. Mkyy2001@163.com.ORCID http://orcid.org/0009-0003-5169-6618
Muyun LiuShenzhen Cellauto Automation Co., Ltd, Shenzhen, China. muyun@ncgt.org.cn.ORCID http://orcid.org/0009-0002-6476-5152

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cellular morphology, a critical manifestation of biological characteristics, is linked to functions. In traditional cell detection, invasive labeling and detection methods not only compromise cellular viability but also entail labor-intensive workflows. Here we presented a non-invasive artificial intelligence framework that integrated deep learning (DL) and machine learning (ML) to predict the immunomodulatory capacity of mesenchymal stem cells (MSCs) through morphological profiling. The improved PreAct-ResNet50 encoder-decoder architecture was used to achieve high-accuracy instance segmentation of cells and nuclei, enabling quantification of morphological features. A LightGBM-based predictive model was subsequently employed to predict MSCs immunomodulatory biomarkers through morphological features. This dual-model system demonstrated satisfactory cell segmentation and biological characteristics prediction capabilities through performance testing. Our method provided an efficient, non- invasive tool for real-time MSCs potency assessment, which could enhance quality controls in cell therapy manufacturing.

Indexed as

Deep LearningImmunomodulationMesenchymal Stem CellsAnimalsBoosting Machine Learning AlgorithmsComputer SimulationHumansPredictive Learning Models

Identifiers

PMID41807585
PMCPMC13230767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.